RE:RE:RE:RE:RE:Interim Datas and speculationsin addition to milestone payments to oncy from adlai, oncy would get double digit royalties on adlai sales in adlai's "territory" once adlai gets any marketing authorization.
re: roche, whether they want to call a combo a to"may"to or a to"mah" to, if that combo contained pela then it could not be sold in adlai's "territory" since adlai has the following:
3.1.1
an exclusive license under the Oncolytics Patent Rights and the Oncolytics Inventions (in each case, to the extent that Oncolytics has exclusive rights and does not infringe Licensee’s Intellectual Property Rights or any Third Party’s Intellectual Property Rights) and Oncolytics’ interest in the Joint Patents to [**] Licensed Products in the Field in the Territory; and
neither roche nor any other entity could do any type of unilateral end run around adlai's exclusive agreement in adlai's territory.
if roche developed anything containing pela and wanted to market that in adlai's territory, then roche (or any other company for that matter) would have to enter into some type of agreement with adlai (which would probably require oncy's approval) which would then seem to trigger the possibility of more royalty payments to oncy.
in return for those milestone payments and double digit royalties, oncy ceeded their rights to pela in the territory given to adlai.
unless oncy lost patent protection for pela and a generic were to be approved, any other entity wanting to market any type of combo in adlai's territory which contained pela is sol.